Business Wire

DELTA-FLY-PHARMA

7.2.2024 12:01:32 CET | Business Wire | Press release

Share
Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.

A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States. Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.

On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

DFP-14927 is an amide bond of DFP-10917 to a carboxylic acid at the end of polyethylene glycol (PEG) with a molecular weight of 40,000, and it is extremely stable in human blood after intravenous administration, allowing for weekly treatment regimen. DFP-14927 is a drug delivery system (DDS) with a mechanism that allows selective release of DFP-10917 into cancer tissues by amidolysis of proteases that are highly expressed in them.

Compared to high molecular weight antibody-drug conjugates (ADCs), medium-sized PEG covalent conjugates are known to have retention in blood vessels around cancer and cancer cell membranes and higher permeability into tumors, and therefore, the concentration of DFP-10917 in cancer tissue can be measured by conventional analysis without the use of radioisotope technology.

Soon after the expected effective concentration of DFP-10917 in cancer tissue is confirmed in the study, we plan to conduct an expanded Phase I study, equivalent to a Phase II clinical trial, in patients with colorectal cancer who have failed existing approved drugs.

The composition of matter patent for DFP-14927 has been granted in the United States, Europe, Asian countries and others, which will enable global marketing of DFP-14927.

In collaboration with leading oncology hospitals in the U.S., we are considering the development of DFP-14927 in haematological cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in addition to solid tumors.

For our future global development and marketing strategy, we are considering collaboration with a major global pharmaceutical company that has strength and expertise in the oncology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207063856/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release

AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr

IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release

The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink

Kinaxis Advances Large-Scale Supply Chain Optimization with NVIDIA AI16.3.2026 21:30:00 CET | Press release

Achieves up to 12X faster end-to-end planning performance in large-scale enterprise models Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced a new milestone in advancing large-scale supply chain optimization within the Kinaxis Maestro™ platform. Maestro already delivers high-performance optimization across complex global supply chains, and Kinaxis is now extending that leadership by leveraging GPU acceleration powered by NVIDIA cuOpt™ and NVIDIA AI infrastructure. As supply chains grow in scale and complexity, planning models must reconcile tens of millions of variables across extended time horizons and multiple planning levels. As model size expands, the number of potential decisions can scale into billions, dramatically increasing computational needs. Organizations are no longer constrained by insight alone. They are constrained by how quickly they can iterate. In testing on a large-scale semiconductor planning model with nearly 50 million decis

Lattice Joins NVIDIA Halos Ecosystem to Advance Safety for Physical AI with Holoscan Sensor Bridge16.3.2026 21:30:00 CET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced it has joined the NVIDIA Halos AI Systems Inspection Lab ecosystem, the first ANSI National Accreditation Board (ANAB) accredited inspection lab for AI-driven physical systems. Announced at the NVIDIA GTC 2026, Lattice will engage with NVIDIA and other Halos ecosystem members to build Halos-certified Holoscan Sensor Bridge-based designs for physical AI and to help shape best practices as the industry evolves. “Physical AI is rapidly moving from controlled environments into the real world, where safety, reliability, and trust are paramount,” said Raemin Wang, Vice President, Segment Marketing, Lattice Semiconductor. “Through this collaboration, Lattice looks forward to contributing our expertise in low power FPGAs and award-winning solution stacks to enable scalable, trusted physical AI systems across robotics, industrial automation, and autonomous applications.” NVIDIA Halos is a comprehensive full

Lenovo Brings Production-Scale AI to Global Sports: Enhancing Fan Experience, Driving Revenue Growth, Boosting Performance, and Improving Operational Efficiency with NVIDIA16.3.2026 21:30:00 CET | Press release

Multiyear collaboration introduces new solutions spanning Sports Intelligence, Operations, and Media & Content. At NVIDIA GTC today, Lenovo (HKSE: 992) (ADR: LNVGY) announced an expanded multiyear collaboration with NVIDIA to help the global sports industry deploy production-scale AI across mission-critical environments, transforming live data into revenue growth, operational resilience, and real-time decision advantage. The global sports technology market is projected to grow from $23 billion in 2025 to more than $60 billion by 2030. Global sports events represent some of the most complex and demanding operating environments in any industry, combining unprecedented scale, technical sophistication, and public visibility. These events engage billions of viewers worldwide, generate and process petabytes of data in real time, and require highly coordinated, distributed operations across multiple countries, all within a context where reliability, resilience, and uninterrupted performance a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye